Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 2:35 pm Purchase | 2024-12-31 | 13G | Applied Therapeutics, Inc. APLT | Vestal Point Capital, LP | 11,500,000 9.900% | 10,355,000 (+904.37%) | Filing History |
| 2025-02-14 2:34 pm Sale | 2024-12-31 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 3,025,000 6.200% | -1,725,000 (-36.32%) | Filing History |
| 2025-02-14 2:33 pm Purchase | 2024-12-31 | 13G | Savara Inc. SVRA | Vestal Point Capital, LP | 10,775,000 6.300% | 10,775,000 (New Position) | Filing History |
| 2025-02-14 2:31 pm Purchase | 2024-12-31 | 13G | Nyxoah S.A. NYXH | Vestal Point Capital, LP | 2,924,216 7.800% | 2,924,216 (New Position) | Filing History |
| 2025-02-14 2:30 pm Purchase | 2024-12-31 | 13G | Immatics N.V. IMTX | Vestal Point Capital, LP | 6,275,000 5.300% | 6,275,000 (New Position) | Filing History |
| 2024-11-14 12:03 pm Purchase | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | Vestal Point Capital, LP | 4,000,000 7.100% | 4,000,000 (New Position) | Filing History |
| 2024-11-14 12:03 pm Purchase | 2024-09-30 | 13G | Passage Bio, Inc. PASG | Vestal Point Capital, LP | 305,000 9.900% | 305,000 (New Position) | Filing History |
| 2024-11-14 12:02 pm Purchase | 2024-09-30 | 13G | Solid Biosciences Inc. SLDB | Vestal Point Capital, LP | 2,800,000 7.300% | 2,800,000 (New Position) | Filing History |
| 2024-11-14 12:02 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vestal Point Capital, LP | 4,000,000 9.300% | 4,000,000 (New Position) | Filing History |
| 2024-11-14 12:02 pm Purchase | 2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX | Vestal Point Capital, LP | 5,028,500 8.900% | 5,028,500 (New Position) | Filing History |
| 2024-11-14 12:01 pm Purchase | 2024-09-30 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 4,750,000 9.800% | 825,000 (+21.02%) | Filing History |
| 2024-11-14 12:00 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Vestal Point Capital, LP | 0 0.000% | -60,000 (Position Closed) | Filing History |
| 2024-11-14 12:00 pm Sale | 2024-09-30 | 13G | Applied Therapeutics, Inc. APLT | Vestal Point Capital, LP | 1,145,000 1.000% | -3,010,000 (-72.44%) | Filing History |
| 2024-02-13 4:34 pm Purchase | 2023-12-31 | 13G | Applied Therapeutics, Inc. APLT | Vestal Point Capital, LP | 4,155,000 5.400% | 4,155,000 (New Position) | Filing History |
| 2024-02-13 4:34 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Vestal Point Capital, LP | 60,000 5.700% | 60,000 (New Position) | Filing History |
| 2024-02-13 4:33 pm Purchase | 2023-12-31 | 13G | uniQure N.V. QURE | Vestal Point Capital, LP | 3,925,000 8.200% | 3,925,000 (New Position) | Filing History |